Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis
Authors:
Open Access
- 21 April 2021
- journal article
- research article
- Published by Springer Nature in BMC Women's Health
- Vol. 21 (1) , 1-12
Abstract
Background: Trastuzumab is currently the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, it is not recommended for HER2-positive breast cancer patients during pregnancy as it may jeopardize safety of the fetus. Nevertheless, there is evidence that fetuses exposed to trastuzumab in early stages of pregnancy remain healthy Methods: To evaluate the possible effects of trastuzumab on fetus and provide evidence on the safety of trastuzumab in early pregnancy in HER2-positive breast cancer patients, we analyzed 22 studies involving 22 pregnant women and 23 fetuses. Results: Based on the meta-analysis, the gestational week of exposure to trastuzumab is 0–34 weeks, the average duration of use is 17 weeks, and the average gestational week of delivery is 34.3 weeks. Complications occurred in 77.27% of patients during pregnancy and 56.52% of newborns。The main complication during pregnancy was anhydramnios (68.18%), while the main complications at birth were Respiratory distress or tachypnea (30%). After an average of 25.28 months of follow-up, 17.39% (4/23) of the children died. There was no complication during pregnancy or at birth in patients treated with trastuzumab during early pregnancy (P = 0.043). Patients older than 30 who received trastuzumab during pregnancy were more likely to have neonatal complications (OR = 7.778, 95%CI = 1.2–50.424, P = 0.04). Conclusion: These results suggest that trastuzumab use during pregnancy can cause pregnancy,fetal and newborn complications. However, exposed to trastuzumab only in the first trimester are less likely to have pregnancy and fetal complications. Patients with gestational age below 30 years are less likely to have neonatal complications after trastuzumab during pregnancy. Terminating pregnancy should not be the only option for such patients. But more evidence is needed to verify this conclusion.Keywords
This publication has 42 references indexed in Scilit:
- Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: A case report and review of the literatureJournal of Obstetrics and Gynaecology Research, 2012
- Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current LiteratureBreast Care, 2011
- Trastuzamab (Herceptin®)-related cardiotoxicity in pregnancyJournal of the Royal Society of Medicine, 2010
- The effects of paclitaxel, dose density, and trastuzumab on treatment‐related amenorrhea in premenopausal women with breast cancerCancer, 2010
- Safety of trastuzumab (Herceptin®) during pregnancy: two case reportsCases Journal, 2009
- Breast cancer and pregnancy: how safe is trastuzumab?Nature Reviews Clinical Oncology, 2009
- Herceptin therapy in pregnancy: Continuation of pregnancy in the presence of anhydramniosJournal of Obstetrics and Gynaecology, 2009
- Favorable pregnancy outcome following Trastuzumab (Herceptin®) use during pregnancy—Case report and updated literature reviewReproductive Toxicology, 2007
- Mitogenic effects of EGF/TGFα and immunolocalization of cognate receptors in human fetal kidneysBioFactors, 1998
- Requirement for neuregulin receptor erbB2 in neural and cardiac developmentNature, 1995